lobbying_activities: 964816
Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API
This data as json
| id | filing_uuid | filing_type | registrant_name | registrant_id | client_name | filing_year | filing_period | issue_code | specific_issues | government_entities | income_amount | expense_amount | is_no_activity | is_termination | received_date |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 964816 | e42ce731-7548-4405-a5ce-22c7a5fcbd2a | Q2 | UNIVERSITY OF KANSAS | 321373 | UNIVERSITY OF KANSAS | 2010 | second_quarter | PHA | Briefing on nanotechnology research for inhaled pharmaceuticals and applicaiton for chemical, biological, radiation, and nuclear responses. Requested statement for congressional hearing related to the University of Kansas and its pharmaceutical research program in neglected and rare diseases. | Army, Dept of (Other),Defense, Dept of (DOD),HOUSE OF REPRESENTATIVES,SENATE,White House Office | 47500 | 0 | 0 | 2010-07-19T16:07:05.837000-04:00 |